New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SCCO;NVS;MOS;ADM;IP From The Last 14 Days
Check below for free stories on SCCO;NVS;MOS;ADM;IP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 8, 2014
09:27 EDTNVSLeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:38 EDTNVSMerus Labs acquires Sintrom from Novartis
Subscribe for More Information
07:33 EDTNVSOphthotech achieves $50M milestone under ex-agreement with Novartis for Fovista
Subscribe for More Information
September 7, 2014
17:15 EDTNVSNovartis presents new data on once-daily Ultibro Breezhaler
Subscribe for More Information
September 5, 2014
06:10 EDTSCCOBuenavista del Cobre mine resumes normal operations with no significant changes
Subscribe for More Information
September 4, 2014
14:23 EDTADMArcher Daniels initiated with a Buy at Janney Capital
Subscribe for More Information
11:49 EDTMOSMosaic initiated with a Buy at Societe Generale
Subscribe for More Information
10:29 EDTIPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:31 EDTIPInternational Paper initiated with a Market Perform at BMO Capital
Subscribe for More Information
September 3, 2014
05:43 EDTNVSNovartis Gilenya data redefining MS treatment goals
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, MA from September 10-13, will add to the growing evidence confirming the importance of redefining treatment goals in multiple sclerosis, or MS. The goal of MS treatment is to have 'no evidence of disease activity' or 'NEDA', which is currently defined as no evidence of relapses, MRI lesions and disability progression. New data to be presented will reinforce the clinical relevance of brain shrinkage and highlight the benefit of including it as a fourth key measure of MS in the definition of NEDA. In addition, other analyses will show that patients treated with Gilenya were more likely to achieve NEDA based on assessment of these four key measures, including MS-related brain shrinkage, than those on placebo. New Gilenya analyses will show how brain shrinkage is associated with future long-term disability progression in patients with MS and that patients with relapsing MS treated with Gilenya had lower rates of brain shrinkage that importantly were sustained over time. The findings will also provide further evidence of the high efficacy of Gilenya on MS disease activity across four key measures.
September 2, 2014
17:28 EDTNVSNovartis heart drug LCZ696 could drive shares to new highs, Barron's says
Subscribe for More Information
10:29 EDTNVSHigh option volume stocks
Subscribe for More Information
09:25 EDTADMCargill acquires Archer Daniels'global chocolate business for $440M
Subscribe for More Information
09:15 EDTADMArcher Daniels to sell global chocolate business to Cargill for $440M
Subscribe for More Information
07:59 EDTNVSElbit Imaging subsidiary announces Gamida Cell completed execution of agreements
Subscribe for More Information
07:01 EDTNVSNovartis volatility expected to move on heart failure drug LCZ696 study
Subscribe for More Information
August 31, 2014
14:04 EDTNVSWorldwide Business Research to hold a conference
Subscribe for More Information
13:47 EDTNVSNovartis heart failure drug LCZ696 shows superiority to enalapril in study
Subscribe for More Information
13:44 EDTADMBarclays to hold a conference
Back-to-School Consumer Conference to be held in Boston on September 3-5.
12:50 EDTNVSEuropean Society of Cardiology to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use